TY  - JOUR

T1  - Anti-thymocyte globulin (ATG)- or alemtuzumab-based graft-versus-host disease prophylaxis in reduced-intensity conditioning allogeneic hematopoietic cell transplantation (HCT) for patients 40 years and older with acute lymphoblastic leukemia in first complete remission: a study from the EBMT Acute Leukemia Working Party

JO  - Bone Marrow Transplantation

UR  - https://doi.org/10.1038/s41409-026-02805-4

PY  - 2026/03/06

AU  - Bug G

AU  - Labopin M

AU  - Byrne JL

AU  - Mielke S

AU  - Orchard K

AU  - Paneesha S

AU  - Potter V

AU  - Blaise D

AU  - Besley C

AU  - Snowden JA

AU  - Yakoub-Agha I et al

ED  - 

DO  - DOI: 10.1038/s41409-026-02805-4

PB  - Springer Science and Business Media LLC

Y2  - 2026/03/17

ER  -